Prognostic factors in T1 bladder urothelial carcinoma: the value of recording millimetric depth of invasion, diameter of invasive carcinoma, and muscularis mucosa invasion

Brimo, Fadi; Wu, Chenbo; Zeizafoun, Nebras; Tanguay, Simon; Aprikian, Armen; Mansure, José João; Kassouf, Wassim

doi:10.1016/j.humpath.2012.04.020

Cited by 77 publications

(83 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Few reports have simultaneously included LVI, muscularis mucosa invasion and the growth pattern for prognostic analysis. 10,11,18,19 In the present study, the presence of LVI and an infiltrative growth pattern were found to be associated with progression, whereas only infiltrative growth pattern was an independent poor prognostic factor for progression (Table 2). Although the presence of LVI has been reported as an unfavorable prognostic factor in T1-BC, and European Association of Urology guidelines recommend that LVI status should be included in pathological reports, the tumor growth patterns of the tumor invasion front have not been widely recognized.…”

Section: Discussionsupporting

confidence: 46%

Exploration of risk factors predicting outcomes for primary T1 high‐grade bladder cancer and validation of the Spanish Urological Club for Oncological Treatment scoring model: Long‐term follow‐up experience at a single institute

et al. 2015

View full text Add to dashboard Cite

Objective: To determine the prognostic factors of primary T1 high-grade bladder cancer and to validate the Spanish Urological Club for Oncological Treatment model in Japanese patients with T1 high-grade bladder cancer treated at a single institution. Methods: Records of 106 patients with T1 high-grade bladder cancer treated from 1998 to 2013 were retrospectively reviewed. Variables included various clinicopathological parameters, including lymphovascular invasion and tumor growth pattern at the invasion front. Recurrence-free survival and progression-free survival were analyzed. Multivariate Cox proportional regression analysis was used to verify the prognostic significance of the variables. Scores for recurrence and progression were calculated using the Spanish Urological Club for Oncological Treatment model. Results: Of 106 patients, 44 (42%) had recurrence and 16 (15%) developed progression after a median (interquartile range) follow-up period of 54 months (range 32-81 months). Non-papillary shape was the only independent predictor for recurrence, while broadbased tumor stalk and infiltrative tumor growth pattern at the invasion front were determined to be independent predictors for progression. Stratification of patients according to the number of progression risk factors yielded hazard ratios of 10.1 and 13.1 in patients having one and two risks, respectively, compared with those without any risks. The Spanish Urological Club for Oncological Treatment model successfully stratified our patients with a trend toward different probabilities of recurrence and progression. Conclusions: The results of the present study might be helpful for counseling certain patients towards intensive treatment, such as radical cystectomy and/or platinum-based systemic chemotherapy. In addition, the Spanish Urological Club for Oncological Treatment model might be applicable to Japanese patients with T1 highgrade bladder cancer.

show abstract

Section: Discussionsupporting

confidence: 46%

Exploration of risk factors predicting outcomes for primary T1 high‐grade bladder cancer and validation of the Spanish Urological Club for Oncological Treatment scoring model: Long‐term follow‐up experience at a single institute

et al. 2015

View full text Add to dashboard Cite

show abstract

“…HER2 presents a potential prognostic factor and may led to HER2 targeted therapy to offer a survival advantage in patients with UBC [1]. A wide variability of HER2 protein overexpression (2 to 85%) has been reported in UBC and was associated with most advanced cancers and poor prognosis [1, 3, 13, 15], but the real frequency could be approximately 5–10% [18, 24]. This variation is due to the use of bladder cancer samples with a varying degree of histological grades and tumor pathological stages [3].…”

Section: Discussionmentioning

confidence: 99%

Expression of human epidermal growth factor receptor 2 in bladder urothelial carcinoma

et al. 2017

View full text Add to dashboard Cite

BackgroundUrothelial bladder carcinoma (UBC) is one of the most prevalent cancers in men worldwide. Human epidermal growth factor receptor 2 (HER2) expression has been detected in a wide range of urothelial carcinoma. Despite many reports in the literature, the prognostic significance of this overexpression remains unclear. The aim of this study was to assess the expression of HER2 in urothelial bladder carcinomas and its association with clinical and pathological parameters.Methods103 cases of UBC were diagnosed in our department between January 2014 and December 2015. The tumor specimens obtained by transurethral resection or cystectomy were evaluated by immunohistochemistry using HER2 antibody.ResultsHER2 protein overexpression was present in 11.7% of cases and associated with tumor grade (p = 0.003) and pathological stage (p = 0.015). In multivariate analysis, HER2 overexpression was associated only with tumor grade (P = 0.04).ConclusionHER2 protein overexpression is noted in patients with high grade cancer. This expression may select patients for anti HER2 targeted therapy. Future larger and prospective studies will verify the frequency of HER2 alteration and the role of HER2 in the aggressive behavior.Electronic supplementary materialThe online version of this article (doi:10.1186/s12907-017-0046-z) contains supplementary material, which is available to authorized users.

show abstract

“…LVI definition was provided in 16 studies (48.5%) and was found in 1 069 of 6194 patients (17.3%). Pathological characteristics are reported in Table . Overall, 62% of patients had NMIBC, 32% had cT2 stage and 6% had cT3–4 stage.…”

Section: Evidence Synthesismentioning

confidence: 99%

A systematic review and meta‐analysis of the impact of lymphovascular invasion in bladder cancer transurethral resection specimens

et al. 2018

View full text Add to dashboard Cite

The aim of the present review was to assess the prognostic impact of lymphovascular invasion (LVI) in transurethral resection (TUR) of bladder cancer (BCa) specimens on clinical outcomes. A systematic review and meta-analysis of the available literature from the past 10 years was performed using MEDLINE, EMBASE and Cochrane library in August 2017. The protocol for this systematic review was registered on PROSPERO (Central Registration Depository: CRD42018084876) and is available in full on the University of York website. Overall, 33 studies (including 6 194 patients) evaluating the presence of LVI at TUR were retrieved. LVI was detected in 17.3% of TUR specimens. In 19 studies, including 2 941 patients with ≤cT1 stage only, LVI was detected in 15% of specimens. In patients with ≤cT1 stage, LVI at TUR of the bladder tumour (TURBT) was a significant prognostic factor for disease recurrence (pooled hazard ratio [HR] 1.97, 95% CI: 1.47-2.62) and progression (pooled HR 2.95, 95% CI: 2.11-4.13), without heterogeneity (I = 0.0%, P = 0.84 and I = 0.0%, P = 0.93, respectively). For patients with cT1-2 disease, LVI was significantly associated with upstaging at time of radical cystectomy (pooled odds ratio 2.39, 95% CI: 1.45-3.96), with heterogeneity among studies (I = 53.6%, P = 0.044). LVI at TURBT is a robust prognostic factor of disease recurrence and progression in non-muscle invasive BCa. Furthermore, LVI has a strong impact on upstaging in patients with organ-confined disease. The assessment of LVI should be standardized, reported, and considered for inclusion in the TNM classification system, helping clinicians in decision-making and patient counselling.

show abstract

Prognostic factors in T1 bladder urothelial carcinoma: the value of recording millimetric depth of invasion, diameter of invasive carcinoma, and muscularis mucosa invasion

Cited by 77 publications

References 29 publications

Exploration of risk factors predicting outcomes for primary T1 high‐grade bladder cancer and validation of the Spanish Urological Club for Oncological Treatment scoring model: Long‐term follow‐up experience at a single institute

Exploration of risk factors predicting outcomes for primary T1 high‐grade bladder cancer and validation of the Spanish Urological Club for Oncological Treatment scoring model: Long‐term follow‐up experience at a single institute

Expression of human epidermal growth factor receptor 2 in bladder urothelial carcinoma

A systematic review and meta‐analysis of the impact of lymphovascular invasion in bladder cancer transurethral resection specimens

Contact Info

Product

Resources

About